ATEC Announces Pricing of Public Offering of Common Stock

Rhea-AI Summary

Alphatec Holdings, Inc. (ATEC) announced a public offering of 11,428,570 shares of its common stock priced at $8.75 per share, aiming for gross proceeds of approximately $100 million. The offering includes a 30-day option for underwriters to purchase an additional 1,714,285 shares. The transaction is expected to close on October 16, 2020, pending customary conditions. This offering is part of ATEC's strategy to enhance its capital for further innovative developments in spine surgery solutions.

Positive

• Projected gross proceeds of approximately $100 million from the offering.
• Funds are intended to support further innovations in spine surgery.

Negative

• Dilution of existing shares due to the public offering.

CARLSBAD, Calif., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (“ATEC”) (NASDAQ: ATEC), a provider of innovative spine surgery solutions dedicated to revolutionizing the approach to spine surgery, today announced the pricing of an underwritten public offering of 11,428,570 shares of its common stock at a public offering price of $8.75 per share. 

The gross proceeds to ATEC from the offering, before underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $100 million. In connection with the offering, ATEC has granted the underwriters a 30-day option to purchase up to an additional 1,714,285 shares of common stock at the public offering price, less underwriting discounts and commissions.  All of the shares in the offering are to be sold by ATEC. The offering is expected to close on October 16, 2020, subject to the satisfaction of customary closing conditions.

Morgan Stanley and Cowen are acting as joint book-running managers in the offering. Canaccord Genuity is acting as lead manager in the offering, with Lake Street Capital Markets and Northland Capital Markets acting as co-managers.

The shares of common stock are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-241677) previously filed with and declared effective by the Securities and Exchange Commission. The offering is being made only by means of a prospectus supplement and the accompanying prospectus. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been previously filed with the SEC and are available on the SEC’s website at www.sec.gov. The final prospectus supplement and accompanying base prospectus will be filed with the SEC and available on the SEC’s website thereafter, and, when available, may also be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or by e-mail at prospectus@morganstanley.com or Cowen and Company, LLC, at c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com.

This press release shall not constitute an offer to sell nor the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. 

About ATEC 

Alphatec Holdings, Inc. (ATEC), through its wholly-owned subsidiaries, Alphatec Spine, Inc. and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction.  ATEC’s Organic Innovation Machine is focused on developing new approaches that integrate seamlessly with the SafeOp Neural InformatiX System to safely and reproducibly treat spine’s various pathologies and achieve the goals of spine surgery.  Alphatec’s vision is to become the Standard Bearer in Spine. 

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. ATEC cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors. The words “believe,” “will,” “should,” “expect,” “intend,” “estimate,” “look forward” and “anticipate,” variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. A further list and description of these and other factors, risks and uncertainties can be found in ATEC’s most recent annual report, any subsequent quarterly and current reports, and certain other filings, filed with the Securities and Exchange Commission. ATEC disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.

Company Contact:
Jeff Black
Chief Financial Officer
investorrelations@atecspine.com

Investor/Media Contact:
Tina Jacobsen
Investor Relations
(760) 494-6790
investorrelations@atecspine.com

FAQ

What is the purpose of ATEC's public offering?

The public offering aims to raise funds for further innovations in spine surgery solutions.

What is the size of the public offering announced by ATEC?

ATEC announced a public offering of 11,428,570 shares at a price of $8.75 per share.

When is ATEC's public offering expected to close?

The public offering is expected to close on October 16, 2020.

What are the potential risks of ATEC's public offering for shareholders?

Shareholders may experience dilution of their existing shares due to the new stock offering.

Who are the underwriters for ATEC's public offering?

Morgan Stanley and Cowen are the joint book-running managers for the offering, with Canaccord Genuity as lead manager.